This report is a summary of the first SRS-Africa meeting that was held virtually on the 15th of October 2021, to gain information on the status of radiopharmaceutical sciences in Africa. Registration data included information on participants' qualifications and field of work. An independent survey performed in Africa prior to the meeting elicited details of available staff in different countries, facilities and equipment, radionuclides and radiopharmaceuticals used, research undertaken and difficulties experienced. We present here a brief overview of this meeting's topics of discussion, including ongoing research, gaps and challenges, and local opportunities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nucmedbio.2022.08.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
EJNMMI Radiopharm Chem
September 2024
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Faculty of Chemistry and Food Chemistry, School of Science, Technical University Dresden (TUD), Dresden, Germany.
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Main Body: This selection of highlights provides commentary on 19 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.
Conclusion: Trends in radiochemistry and radiopharmacy are highlighted.
Visualisation of in vivo protein synthesis during mycobacterial infection through [Ga]Ga-DOTA-puromycin µPET/MRI.
Sci Rep
August 2024
Nuclear Medicine Research Infrastructure NPC, Pretoria, 0001, South Africa.
Radiolabelled puromycin analogues will allow the quantification of protein synthesis through nuclear medicine-based imaging. A particularly useful application could be the non-invasive longitudinal visualisation of mycobacterial activity through direct quantification of puromycin binding. This study assesses the value of [Ga]Ga-DOTA-puromycin in the visualisation of mycobacteria through positron emission tomography combined with magnetic resonance imaging (µPET/MRI).
View Article and Find Full Text PDFPosition paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework.
EJNMMI Radiopharm Chem
January 2024
Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
Background: Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access to and availability of radiopharmaceuticals.
Main Body: This paper summarises major considerations for a suitable pharmaceutical regulatory framework to facilitate patient access to radiopharmaceuticals.
Quality audits of nuclear medicine practices in a middle-income African setting.
J Med Radiat Sci
June 2024
Department of Radiography, School of Radiography, School of Allied Health Sciences, Faculty of Health Sciences and Veterinary Medicine, University of Namibia, Windhoek, Namibia.
Introduction: The International Atomic Energy Agency (IAEA) introduced a Quality Management Audits in Nuclear Medicine (QUANUM) programme, to improve nuclear medicine practice standards aligned with international standards through self-assessments. The absence of quality management audits in nuclear medicine departments could potentially result in a compromise in the safety and quality of patient care. To date, there is no evidence that quality audits have been conducted in nuclear medicine departments of this middle-income country.
View Article and Find Full Text PDFHighlight selection of radiochemistry and radiopharmacy developments by editorial board.
EJNMMI Radiopharm Chem
October 2023
Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Main Body: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.
Conclusion: Trends in radiochemistry and radiopharmacy are highlighted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!